Log In
Print
BCIQ
Print
Print this Print this
 

Lexiscan, Rapiscan, regadenoson (CVT-3146)

  Manage Alerts
Collapse Summary General Information
Company Gilead Sciences Inc.
DescriptionShort-acting adenosine A2A receptor (ADORA2A) agonist
Molecular Target Adenosine A2A receptor (ADORA2A)
Mechanism of ActionAdenosine A2A receptor agonist; Diagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationCardiovascular, Diagnostic
Indication DetailsPharmacologic stress agent in cardiac perfusion imaging studies; Pharmacologic stress agent in myocardial perfusion imaging (MPI) studies; Pharmacologic stress agent in myocardial perfusion imaging (MPI) studies in patients with asthma or chronic obstructive pulmonary disease (COPD)
Regulatory Designation

Partner

Astellas Pharma Inc.; General Electric Co.; Rapidscan Pharma Solutions Inc.


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

$1,400.0M

$1,400.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today